The lncRNA H19 positively affects the tumorigenic properties of glioblastoma cells and contributes to NKD1 repression through the recruitment of EZH2 on its promoter

Barbara Fazi, Sabrina Garbo, Nicola Toschi, Annunziato Mangiola, Malinska Lombari, Daria Sicari, Cecilia Battistelli, Silvia Galardi, Alessandro Michienzi, Gianluca Trevisi, Rona Harari-Steinfeld, Carla Cicchini, Silvia Anna CiafrèOncotarget 2018 · DOI

TL;DR

This study reveals that the long noncoding RNA (lncRNA) H19 plays a significant role in glioblastoma (GBM) by promoting tumor cell growth, migration, and invasion. H19 achieves this by recruiting the epigenetic regulator EZH2 to the promoter of the NKD1 gene, leading to its repression and consequently impacting the Wnt pathway, a critical pathway in cancer progression.

What Problem Does This Paper Address?

Glioblastoma (GBM) is an aggressive brain tumor with a poor prognosis, and its underlying molecular mechanisms are still not fully understood. Long noncoding RNAs (lncRNAs) have emerged as crucial regulators of gene expression, and H19, a well-known "oncofetal" lncRNA, has been implicated in various cancers. While H19's oncogenic role in GBM has been suggested, the precise molecular mechanisms by which it contributes to tumor progression remained unclear. This paper aims to elucidate H19's function in GBM by investigating its interaction with the epigenetic machinery, specifically the Polycomb Repressive Complex 2 (PRC2) component EZH2, and its impact on target gene regulation.

Methods

The researchers employed a multi-pronged approach:

  • Factor Analysis: They used a factor analysis on a SAGE dataset of 12 GBM samples to identify genes whose expression correlates with H19.
  • In Vitro Functional Assays:
    • H19 Knockdown: They used siRNAs to reduce H19 expression in GBM cell lines (A172 and LN229).
  • Viability, Migration, and Invasion Assays: Standard MTS assays, transwell migration, and invasion assays were performed to assess the functional consequences of H19 knockdown.
  • RNA Fluorescence In Situ Hybridization (FISH): This technique was used to visualize the subcellular localization of H19 in GBM cells.
  • RNA Immunoprecipitation (RIP): RIP assays were conducted to demonstrate the physical binding of H19 to EZH2.
  • Chromatin Immunoprecipitation (ChIP): ChIP assays were used to assess the binding of EZH2 and the presence of H3K27 trimethylation (a mark associated with gene repression) at the promoters of target genes, particularly NKD1.
  • Western Blotting: Used to measure protein levels of NKD1 and global H3K27 trimethylation.
  • RT-qPCR: Employed for quantifying RNA expression levels of H19, NKD1, and miR-675.

Datasets

  • SAGE Dataset: A dataset of 12 glioblastoma samples was used for factor analysis to correlate H19 expression with other genes.
  • Oncomine Database: Publicly available glioblastoma datasets from Oncomine were used to confirm the overexpression of H19 in GBM tissues compared to healthy brain controls.
  • Human Glioblastoma Cell Lines: Five human glioblastoma cell lines (U87, A172, LN229, LN18, T98G) were used for H19 expression analysis and subsequent functional studies.

Key Insights and Ideas

  • H19 as a Driver of GBM Aggressiveness: The study provides strong evidence that H19 actively promotes key oncogenic features of GBM cells, including their ability to survive, migrate, and invade.
  • Epigenetic Regulation via EZH2 Recruitment: A central finding is that H19 acts as a molecular scaffold, recruiting EZH2 to specific gene promoters. This interaction is crucial for H19's function.
  • NKD1 Repression as a Key Mechanism: The paper identifies NKD1, a negative regulator of the Wnt pathway, as a direct target of H19-mediated repression. This repression is achieved through EZH2-induced H3K27 trimethylation of the NKD1 promoter.
  • Wnt Pathway Involvement: The repression of NKD1, which normally inhibits the Wnt pathway, suggests that H19 indirectly promotes Wnt signaling, a known driver of cancer progression.
  • Nuclear Localization of H19: For the first time, the study demonstrates H19's presence in the nuclear compartment of highly expressing GBM cells, supporting its role as an epigenetic modulator.
  • miR-675 Independence: The functional effects of H19 were shown to be largely independent of its role as a precursor for miR-675, highlighting H19's direct lncRNA functions.

Key Results

  • H19 expression was significantly elevated in glioblastoma tissues and cell lines compared to healthy controls.
  • Knockdown of H19 reduced the viability, migration, and invasiveness of A172 and LN229 glioblastoma cell lines.
  • H19 expression was inversely correlated with NKD1 expression; H19 knockdown led to increased NKD1 mRNA and protein levels.
  • H19 was shown to physically bind to EZH2 in glioblastoma cells.
  • H19 depletion resulted in a global decrease in H3K27 trimethylation.
  • EZH2 binding to the NKD1 promoter was reduced upon H19 silencing, accompanied by a decrease in H3K27 trimethylation at this locus.
  • H19 also influenced EZH2 binding to the MYT1 promoter, another gene involved in neural differentiation.

Limitations and Future Work

  • Cell Line Specificity: While two cell lines (A172 and LN229) were used for detailed functional studies, the findings might not be universally applicable to all GBM subtypes or patient-derived cells. The authors note differences in the magnitude of H19's effect between these two lines.
  • miR-675 Levels: The study found undetectable levels of miR-675-5p in the tested cell lines, which simplifies the interpretation of H19's direct lncRNA functions but might not reflect all GBM contexts.
  • MYT1 Induction: While H19 depletion affected EZH2 binding to the MYT1 promoter, MYT1 protein levels did not significantly increase, suggesting other factors are required for its induction. The authors speculate that other signals necessary for MYT1 induction might be missing in their cell models.
  • Future Directions: The authors suggest that their findings provide a new piece to the complex puzzle of H19 function in glioblastoma, implying further research into the broader epigenetic modulation program orchestrated by H19 and EZH2. Investigating the therapeutic potential of targeting this H19-EZH2-NKD1 axis in GBM could be a promising avenue.

Summary updated

Abstract

The still largely obscure molecular events in the glioblastoma oncogenesis, a primary brain tumor characterized by an inevitably dismal prognosis, impel for investigation. The importance of Long noncoding RNAs as regulators of gene expression has recently become evident. Among them, H19 has a recognized oncogenic role in several types of human tumors and was shown to correlate to some oncogenic aspects of glioblastoma cells. Here we, hypothesyze that in glioblastoma H19 exerts its function through the interaction with the catalytic subunit of the PRC2 complex, EZH2. By employing a factor analysis on a SAGE dataset of 12 glioblastoma samples, we show that H19 expression in glioblastoma tissues correlates with that of several genes involved in glioblastoma growth and progression. H19 knock-down reduces viability, migration and invasiveness of two distinct human glioblastoma cell lines. Most importantly, we provide a mechanistic perspective about the role of H19 in glioblastoma cells, by showing that its expression is inversely linked to that of NKD1, a negative regulator of Wnt pathway, suggesting that H19 might regulate NKD1 transcription via EZH2-induced H3K27 trimethylation of its promoter. Indeed, we showed that H19 binds EZH2 in glioblastoma cells, and that EZH2 binding to NKD1 and other promoters is impaired by H19 silencing. In this work we describe H19 as part of an epigenetic modulation program executed by EZH2, that results in the repression of Nkd1. We believe that our results can provide a new piece to the complex puzzle of H19 function in glioblastoma.
BibTeX
@inproceedings{fazi2018lncrna,
  author = {Barbara Fazi and Sabrina Garbo and Nicola Toschi and Annunziato Mangiola and Malinska Lombari and Daria Sicari and Cecilia Battistelli and Silvia Galardi and Alessandro Michienzi and Gianluca Trevisi and Rona Harari-Steinfeld and Carla Cicchini and Silvia Anna Ciafrè},
  title = {{The lncRNA H19 positively affects the tumorigenic properties of glioblastoma cells and contributes to NKD1 repression through the recruitment of EZH2 on its promoter}},
  booktitle = {Oncotarget},
  year = {2018},
  doi = {10.18632/oncotarget.24496},
}
Figure